Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Asset Resilience Ratio
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has an Asset Resilience Ratio of 9.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002940 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. See Zhejiang Anglikang Pharmaceutical Co Ltd (002940) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Anglikang Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002940 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥283.96 Million | 9.11% |
| Total Liquid Assets | CN¥283.96 Million | 9.11% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Anglikang Pharmaceutical Co Ltd Class A maintains only 9.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Anglikang Pharmaceutical Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.47% | CN¥102.26 Million ≈ $14.96 Million |
CN¥2.95 Billion ≈ $431.80 Million |
+2.25pp |
| 2024-12-31 | 1.21% | CN¥36.04 Million ≈ $5.27 Million |
CN¥2.97 Billion ≈ $435.27 Million |
+0.88pp |
| 2023-12-31 | 0.33% | CN¥10.00 Million ≈ $1.46 Million |
CN¥3.02 Billion ≈ $441.92 Million |
-2.34pp |
| 2022-12-31 | 2.67% | CN¥69.30 Million ≈ $10.14 Million |
CN¥2.60 Billion ≈ $379.89 Million |
-0.19pp |
| 2021-12-31 | 2.86% | CN¥59.60 Million ≈ $8.72 Million |
CN¥2.08 Billion ≈ $304.89 Million |
+2.94pp |
| 2020-12-31 | -0.08% | CN¥-1.53 Million ≈ $-224.55K |
CN¥1.94 Billion ≈ $283.99 Million |
-7.30pp |
| 2019-12-31 | 7.22% | CN¥100.05 Million ≈ $14.64 Million |
CN¥1.38 Billion ≈ $202.67 Million |
+3.48pp |
| 2018-12-31 | 3.75% | CN¥55.08 Million ≈ $8.06 Million |
CN¥1.47 Billion ≈ $215.14 Million |
-- |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengz… Read more